Inferra AI / Company / QDEL

QuidelOrtho Corp

QDEL · Health Care

Last earnings Aug 6, 2026

Key results

Care revenuequarter

$113 million

Key First Quarter 2026 Results (all comparisons are to the prior year period) Total revenu e was $620 million , as reported Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025.

SEC original ↗QuidelOrtho Corp — Earnings release (8-K exhibit)EX-99May 5, 2026

Labs revenuequarter

$353 million

Labs revenue of $353 million declined by 5% as reported and 8% in constant currency, primarily due to slower distributor sales in China that the Company believes is related to pending changes to the

SEC original ↗QuidelOrtho Corp — Earnings release (8-K exhibit)EX-99May 5, 2026

Immunohematology revenuequarter

$138 million

Immunohematology revenue of $138 million grew 8% as reported and 3% in constant currency, primarily driven by growth in North America, China and JPAC.

SEC original ↗QuidelOrtho Corp — Earnings release (8-K exhibit)EX-99May 5, 2026

AI analysis

Q1 2026 · reported May 5, 2026

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Care revenue · Q1 2026

$113M

EX-99 · May 5, 2026

Labs revenue · Q1 2026

$353M

EX-99 · May 5, 2026

Immunohematology revenue · Q1 2026

$138M

EX-99 · May 5, 2026

The quarter in charts

Segment mix

Business-unit revenue, as stated

Segment revenue figures as stated in the event record.

Headline figures

Metric	Q1 2026	Prior qtr	Year ago
Care revenue	$113 million	—	—
Labs revenue	$353 million	—	—
Immunohematology revenue	$138 million	—	—

EX-99 · May 5, 2026

Guidance · company-stated

Direction: Initiated

Company outlook — Initiated

“Full-year 2026 Financial Guidance The Company provided its initial financial guidance for full-year 2026 on February 11, 2026.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

The Company s corporate function also includes debt and stock-based compensation associated with all employee stock-based awards.

The CODM does not review and is not provided capital expenditures, total depreciation and amortization or assets by segment, and therefore this information has been excluded as it does not comprise part of management s key performance metrics.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

QuidelOrtho Reports First Quarter 2026 Financial Results LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics Key Product Launches in U.S

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Initiated

Company outlook — Initiated (“initial”)
“Full-year 2026 Financial Guidance The Company provided its initial financial guidance for full-year 2026 on February 11, 2026.”

Classified from the release's primary full-year outlook statement.

Capital allocation

The Company s corporate function also includes debt and stock-based compensation associated with all employee stock-based awards.

SEC original ↗QuidelOrtho Corp — 10-Q Quarterly report10-QAug 7, 2026

The Credit Agreement consists of (i) a $ 1.15 billion Term Loan A, (ii) a $ 100.0 million DDTL Term Loan A (together with the Term Loan A, the Term Loan A Facilities ), (iii) a $ 1.45 billion Term Loan B (collectively with the Term Loan A Facilities, the Term Loans ) and (iv) a $ 700.0 million Revolving Credit Facility.

SEC original ↗QuidelOrtho Corp — 10-Q Quarterly report10-QAug 7, 2026

Availability under the Revolving Credit Facility, after 16 deducting letters of credit of $ 23.5 million and $ 250.0 million borrowings outstanding, was $ 426.5 million as of June 28, 2026.

SEC original ↗QuidelOrtho Corp — 10-Q Quarterly report10-QAug 7, 2026

During the six months ended June 28, 2026, the Company (i) made $ 36.0 million in payments on the Term Loans and (ii) borrowed $ 385.0 million and made $ 215.0 million in payments on the Revolving Credit Facility.

SEC original ↗QuidelOrtho Corp — 10-Q Quarterly report10-QAug 7, 2026

In April 2026, the Company borrowed $ 100.0 million under the DDTL Term Loan A, comprised of a Term SOFR loan to fund the acquisition of LEX Diagnostics and for general corporate purposes.

SEC original ↗QuidelOrtho Corp — 10-Q Quarterly report10-QAug 7, 2026

Strategy & priorities

We also advanced our key strategic priorities, including the U.

SEC original ↗QuidelOrtho Corp — Earnings release (8-K exhibit)EX-99May 5, 2026

These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho s commercial and other strategic goals, financial guidance for 2026 and related assumptions and other future financial condition and operating results, including growth expectations and expected results of operations, financial position or cost-savings and operational improvement initiatives, and other future plans, objectives, strategies, expectations and intentions.

SEC original ↗QuidelOrtho Corp — Earnings release (8-K exhibit)EX-99May 5, 2026

Without limiting the foregoing, the words may, will, could, would, should, might, expect, anticipate, believe, estimate, plan, intend, goal, project, strategy, future, continue, aim, strive, seek or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements.

SEC original ↗QuidelOrtho Corp — Earnings release (8-K exhibit)EX-99May 5, 2026

Risks & headwinds

Such statements are based on the beliefs and expectations of QuidelOrtho s management as of the date of this press release and are subject to significant known and unknown risks and uncertainties.

SEC original ↗QuidelOrtho Corp — Earnings release (8-K exhibit)EX-99May 5, 2026

Legal Proceedings 35 ITEM 1A.

SEC original ↗QuidelOrtho Corp — 10-Q Quarterly report10-QAug 7, 2026

The Bristol County Complaint seeks a judgment determining that the lawsuit can be maintained as a class action and awarding the plaintiff and putative class damages, pre- and post-judgment interest, attorneys and experts fees, and costs.

SEC original ↗QuidelOrtho Corp — 10-Q Quarterly report10-QAug 7, 2026

The Company is not able to estimate a possible loss or range of loss that may result from these lawsuits or to determine whether such loss, if any, would have a material adverse effect on its business, financial condition, results of operations or liquidity.

SEC original ↗QuidelOrtho Corp — 10-Q Quarterly report10-QAug 7, 2026

From time to time, the Company is involved in litigation and other legal proceedings, including matters related to product liability claims, commercial disputes and intellectual property claims, as well as regulatory, employment, and other claims related to its business.

SEC original ↗QuidelOrtho Corp — 10-Q Quarterly report10-QAug 7, 2026

Documents

Earnings deck slides

0 decks with slide view

QuidelOrtho Corp — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors